MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada
Copenhagen, December 18, 2026 – MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, today announced that their Canadian partner Knight Therapeutics Inc. (TSX: GUD) has obtained regulatory approval of Wynzora® Cream for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks in Canada.
In November 2024, MC2 Therapeutics entered a License and Commercialization Agreement with Endo, Inc. (OTCQX: NDOI), through its subsidiary Paladin Pharma Inc. under which they were granted exclusive rights to commercialize MC2’s Wynzora® Cream in Canada and in June 2025 Knight Therapeutics Inc. (TSX: GUD) acquired Paladin Pharma Inc. This approval and pending launch marks yet another important step in our commitment to making Wynzora® available to more people living with psoriasis globally.
For more information, kindly see:
Knight Therapeutics – Building a leading specialty pharmaceutical company
BACK
